Clinical Trial Update: Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants [Phase 2]

View source ↗

Summary

This open-label Phase 2 trial evaluating rilzabrutinib in immunoglobulin G4-related disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Principia Biopharma, a Sanofi Company | Conditions: Immunoglobulin G4 Related Disease | Phase 2 | Status: COMPLETED